30-day average of 18 articles · scale −100 to +100
Across 18 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Bristol-Myers Squibb Company news is Somewhat Bullish (+40)
on a scale from −100 to +100.
That is up 10 points from the previous 30 days (+30).
📈 BMY stock returned 40.5% over three years, trading near $62.91.
💰 Company generated $9.3 billion in free cash flow last twelve months.
Slightly Bullish +15
Bristol Myers Squibb (BMY) Stock Looks Below Fair Value Following A 41% ...
AI-generated analysis
Key insights
📈 BMY stock has returned approximately 40.5% over the past three years, trading near $62.91 per share.
💰 The company generated about $9.3 billion in free cash flow over the last twelve months according to the analysis.
🔬 Recent positive data for Camzyos and new approvals for ZENBEXUS are expected to support future drug-driven cash flows.
⚠️ Investors face a projected revenue step-down from Eliquis beginning in 2027 as part of the company's lifecycle management.
💡 A bullish narrative suggests BMY is 21% undervalued if late-stage platforms like CAR-T and ADCs succeed commercially.
📉 A bearish perspective argues the stock is 121% overvalued at current levels, with price being the primary sticking point.
💸 The company has implemented a plan to generate $2 billion in cost savings to offset revenue shifts.
🧠 Simply Wall St analysis indicates the fair value depends on successfully converting late-stage platforms into meaningful products.
📈 Bullish signals
🔬Recent trial results for Camzyos and new product approvals for ZENBEXUS are expected to support expectations for future drug-driven cash flows.
💡The company has a solid pipeline story with late-stage platforms in areas like CELMoDs, CAR-T, ADCs, Factor XI inhibition, and neuroscience that could convert into commercially meaningful products.
💡A bullish analyst narrative suggests the stock is 21% undervalued if the company successfully manages revenue transitions from legacy assets like Eliquis.
📉 Risk factors
💰The DCF model assumes a gently declining free cash flow pattern over the next decade as major products mature and new launches fill gaps only gradually.
📉A bearish investor narrative argues the stock is 121% overvalued at current levels, stating that the entry price exceeds fair value filters despite the company's quality.
⚠️The analysis projects a step-down in revenue from Eliquis starting in 2027, which constrains growth assumptions in the valuation model.
Article
Bristol-Myers Squibb (BMY) shares have appreciated approximately 40.5% over the past three years, trading around $62.91 per share. The article analyzes whether this valuation is justified by the company's long-term cash flow generation capabilities, utilizing a Discounted Cash Flow (DCF) model that projects free cash flow of roughly $9.3 billion over the last twelve months.
The analysis suggests BMY may be undervalued based on intrinsic value calculations derived from its cash flow profile. Key drivers supporting this view include recent positive trial results for Camzyos and new product approvals for ZENBEXUS, which are expected to bolster future drug-driven cash flows despite anticipated revenue declines from the legacy asset Eliquis starting in 2027.
Simply Wall St presents a split narrative regarding BMY's fair value. A bullish perspective argues the stock is 21% undervalued if the company successfully commercializes its late-stage platforms in areas like CAR-T and ADCs while managing revenue transitions. Conversely, a bearish view contends the stock is 121% overvalued at current levels, citing that the entry price exceeds fair value filters despite the underlying quality of the business.
The article concludes by emphasizing the importance of leadership strategy in shaping BMY's future trajectory. It notes that while the company has a solid pipeline and cost-saving plans totaling $2 billion, investors must weigh these factors against the specific assumptions regarding growth margins and earnings required to justify the current market price.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Bristol-Myers Squibb (NYSE:BMY) is identified as a high-priority candidate for technical breakout strategies, achieving a perfect technical rating of 10 out of 10 and a setup quality score of 9 out of 10. The stock demonstrates strong trend strength across multiple timeframes with major moving averages pointing higher, indicating it has successfully attracted market participants and is building a base near a logical entry point rather than being overextended.
The analysis outlines a specific trading plan for BMY, suggesting a buy stop order at $68.10 just above the resistance zone and a stop-loss at $65.90. This structure defines a potential loss of 2.20 points (approximately 3.23%) per trade, with a suggested position size that limits total portfolio risk to around 0.81%. The setup implies that prices have been consolidating, providing a defined trigger for entry and a clear failure point if the stock fails to reach the buy stop.
Beyond technical metrics, BMY is highlighted for generating strong free cash flow relative to its market price and belonging to a more stable, less cyclical segment of the market. The company has exhibited more stable recent price behavior compared to typical market movers, reinforcing its status as a leading stock with a better chance of following through after breaking resistance levels.
📈 BMY achieves perfect technical rating of 10/10 with strong trend strength.
🛡️ Trade limits loss to 3.23% and portfolio risk to 0.81%.
📉 Major moving averages point higher as stock builds a base.
📈 Bristol-Myers Squibb achieves a perfect technical rating of 10 out of 10 and a setup quality score of 9 out of 10, confirming strong trend strength and a logical entry base.
📊 The stock exhibits stable recent price behavior and belongs to a less cyclical market segment compared to typical movers.
💰 BMY generates strong free cash flow relative to its current market price, supporting its financial stability.
🎯 A specific trading plan suggests a buy stop at $68.10 above resistance with a stop-loss at $65.90.
🛡️ The defined trade structure limits potential loss to 2.20 points (3.23%) and caps total portfolio risk at approximately 0.81%.
📉 Major moving averages are pointing higher, indicating that the stock is building a base rather than being overextended.
Belongs to stable segment with less cyclical behavior than typical movers.
Bullish Signals
Bristol-Myers Squibb achieves a perfect technical rating of 10 out of 10 and a setup quality score of 9 out of 10, confirming strong trend strength and a logical entry base.
The stock generates strong free cash flow relative to its market price, indicating robust financial health.
BMY belongs to a more stable, less cyclical segment of the market with more stable recent price behavior than typical market movers.
Nykredit A/S purchased 506,199 shares of Bristol Myers Squibb (BMY) in the second quarter, valued at approximately $29.2 million, contributing to institutional ownership of 76.41%. The company reported strong quarterly financials with earnings per share of $2.04, beating estimates of $1.60, and revenue rising 5.7% year-over-year to $12.97 billion.
Bristol Myers Squibb maintains a quarterly dividend of $0.63 per share, yielding 3.7%, while analysts hold a consensus 'Moderate Buy' rating with an average price target of $66.06. Recent positive sentiment is driven by encouraging long-term data for the heart-failure drug Camzyos from the EXPLORER-LTE study, which supports its growth trajectory.
However, the company faces pipeline risks as it voluntarily paused enrollment in zola-cel autoimmune cell-therapy trials due to inflammatory side effects. This pause raises concerns about the safety profile of experimental therapies and may increase scrutiny on trial-disclosure practices, particularly following similar halts by Novartis.
Analyst sentiment remains mixed with recent rating changes: Sanford C. Bernstein upgraded BMY to 'outperform,' Raymond James initiated a 'strong-buy' rating, and Piper Sandler assigned an 'overweight' rating, while Jefferies cut its rating to 'hold.' The stock trades at a P/E ratio of 14.99 with a market capitalization of $139.03 billion.
📈 Nykredit acquired $29.2M BMY position in Q2.
💰 EPS beat estimates at $2.04 vs $1.60.
📈 Revenue rose 5.7% YoY to $12.97B.
⚠️ Zola-cel trials paused due to inflammatory side effects.
🔬 Camzyos long-term data supports positive investor sentiment.
📈 Nykredit A/S acquired a new position in BMY worth approximately $29.2 million during the second quarter.
💰 Bristol Myers Squibb reported quarterly EPS of $2.04, significantly beating analyst estimates of $1.60.
📈 Revenue increased 5.7% year-over-year to reach $12.97 billion in the latest quarter.
💸 The company pays a quarterly dividend of $0.63 per share, offering a 3.7% annualized yield.
🔬 Positive investor sentiment is supported by encouraging long-term data for Camzyos from the EXPLORER-LTE study.
⚠️ Bristol Myers Squibb paused enrollment in zola-cel autoimmune trials due to inflammatory side effects.
📉 The trial pause raises concerns about the risk profile of experimental cell therapy programs.
🔍 Novartis and BMY halted autoimmune trials following deaths or serious side effects, reinforcing safety concerns.
📊 Analysts rate BMY a 'Moderate Buy' with an average price target of $66.06.
🚀 Sanford C. Bernstein upgraded BMY from 'market perform' to 'outperform' in late August.
🔥 Raymond Financial initiated coverage with a 'strong-buy' rating on the stock.
⚖️ Piper Sandler initiated coverage assigning an 'overweight' rating to Bristol Myers Squibb shares.
📉 Jefferies Financial Group cut its rating from 'buy' to 'hold' in late August.
📈 The stock opened at $68.06, trading above its 50-day and 200-day moving averages.
🏢 Corporate insiders own a minimal 0.05% of the company's outstanding shares.
Bullish Signals
Bristol Myers Squibb reported quarterly EPS of $2.04, beating analyst estimates of $1.60 by $0.44.
Revenue rose 5.7% year-over-year to $12.97 billion, exceeding the consensus estimate of $11.74 billion.
Encouraging long-term data for Camzyos from the EXPLORER-LTE study supports renewed investor interest and growth expectations.
Institutional ownership remains strong at 76.41%, with Nykredit A/S adding a $29.2 million position in Q2.
Analysts have upgraded or initiated coverage with bullish ratings, including 'outperform' from Sanford C. Bernstein and 'strong-buy' from Raymond James.
The stock trades at a P/E ratio of 14.99 with a market capitalization of $139.03 billion, reflecting solid valuation metrics.
Analysts forecast FY 2026 EPS between 6.75 and 7.00, indicating continued growth expectations.
Risk Factors
Bristol Myers Squibb voluntarily paused enrollment in zola-cel autoimmune trials after inflammatory side effects emerged.
The trial pause raises concerns about the therapy's risk profile and may delay a potentially important pipeline program.
Broader reporting that Novartis and BMY halted autoimmune trials following deaths or serious side effects reinforces safety concerns.
RBC Capital maintained a 'Hold' rating, noting that the stock's strong run may already incorporate much of the favorable news.
Corporate insider SVP Phil M. Holzer sold 500 shares in late August, representing a 2.88% decrease in his position.
Simply Wall St analysis suggests Bristol-Myers Squibb (BMY) stock is undervalued by approximately 46.3%, trading at $63.83 per share against a Discounted Cash Flow (DCF) intrinsic value estimate of roughly $119. The company has delivered a 38.1% gain over the past year, yet valuation metrics including P/E multiples indicate it remains cheaper than industry and peer averages.
The analysis highlights specific catalysts supporting future cash flows, including the FDA's accelerated approval of ZENBEXUS for multiple myeloma and plans to build a US$2.3 billion manufacturing campus in Houston. Conversely, risks include a revived lawsuit regarding Celgene contingent value rights worth US$6.7 billion and significant upcoming patent cliffs for blockbuster drugs like Eliquis and Opdivo.
Valuation comparisons show BMY trading at a P/E of 14.0x, which is below the Pharmaceuticals industry average of 16.9x and significantly lower than the peer group average of 58.4x. The model implies a fair P/E ratio of 18.2x, suggesting the market is pricing in lower earnings multiples than warranted by the company's size and profitability profile.
The article concludes that while the discount may reflect genuine mispricing offering a margin of safety for investors, it could also serve as compensation for legal overhangs and patent expiries. The key determinant for future performance will be whether BMY can sustain its cash flows by offsetting revenue erosion from generic competition with its robust pipeline and strategic investments.
📊 BMY estimated 46.3% undervalued with $119 intrinsic value.
📊 Bristol-Myers Squibb (BMY) is estimated to be 46.3% undervalued based on a Discounted Cash Flow model projecting an intrinsic value of approximately $119 per share.
📈 The stock has delivered a strong 38.1% return over the past year, though recent gains have not fully eliminated potential upside according to current valuation signals.
💊 The FDA granted accelerated approval for ZENBEXUS to treat multiple myeloma, providing a new revenue stream and supporting future cash flow projections.
🏗️ The company plans to construct a US$2.3 billion manufacturing campus in Houston to support production capabilities.
⚖️ A revived legal dispute concerning Celgene contingent value rights poses a potential financial risk with an exposure of approximately US$6.7 billion.
📉 BMY trades at a P/E ratio of 14.0x, which is below the industry average of 16.9x and far below the peer group average of 58.4x.
⏳ Upcoming patent cliffs for major drugs like Eliquis (generic in 2028) and Opdivo present risks to long-term revenue growth due to generic and biosimilar competition.
🎯 The DCF model assumes last twelve month free cash flow of about US$11.5b, with projections holding steady rather than assuming aggressive expansion.
📉 Community sentiment is divided between a bull case citing breakthrough partnerships like BioNTech and a bear case warning of patent erosion risks.
Bullish Signals
38.1% gain over past year.
FDA approved ZENBEXUS asset.
$2.3B Houston manufacturing campus.
P/E 14.0x vs industry 16.9x.
Fair P/E 18.2x implies discount.
Risk Factors
Revived lawsuit exposes company to ~US$6.7 billion financial risk.
Patent cliffs for Eliquis (2028) and Opdivo raise generic competition risks.
Conservative DCF model limits upside if growth falls short of expectations.
Bullish Signals
The stock is trading at a significant discount to its estimated intrinsic value, offering a potential margin of safety for valuation-focused investors.
Recent share price performance shows a 38.1% gain over the past year, indicating improving market sentiment toward the company.
The FDA's accelerated approval of ZENBEXUS adds a new therapeutic asset to the pipeline, supporting long-term revenue expectations.
The planned US$2.3 billion manufacturing campus in Houston demonstrates commitment to operational capacity and future growth.
Current P/E multiple of 14.0x is substantially lower than both the industry average (16.9x) and peer group average (58.4x), suggesting undervaluation relative to peers.
The DCF model implies a fair P/E ratio of 18.2x, indicating the market is currently pricing earnings at a discount to the company's fundamental profile.
Risk Factors
A revived lawsuit regarding Celgene contingent value rights creates a specific legal and financial risk with an exposure of approximately US$6.7 billion.
Significant upcoming patent cliffs for blockbuster drugs like Eliquis (generic in 2028) and Opdivo raise the risk of generic and biosimilar competition impacting long-term revenue.
The DCF model assumes cash flows will broadly hold around current levels rather than aggressive expansion, which may limit upside potential if growth is slower than expected.
Bristol-Myers Squibb (BMY) concluded the second quarter with a strong performance, driving its stock price to a 52-week high of $64.96 on June 28. The company reported Q2 revenue of $12.97 billion, representing a 12.9% increase quarter-over-quarter. Non-GAAP earnings per share surged 39.7% year-over-year and 29.1% quarter-over-quarter to reach $2.04, significantly beating the author's base case scenario.
Following the earnings release, Bristol-Myers Squibb raised its full-year 2026 diluted EPS guidance from a previous range of $6.05-$6.35 to a new target of $6.75-$7. The rally is attributed to promising efficacy data for Iza-Bren in triple-negative breast cancer and sustained strong demand for key products Opdivo Qvantig and Breyanzi. The article concludes that the stock's risk/reward profile remains attractive despite recent gains.
The author, representing Allka Research, highlights the conservative investment approach and substantial returns associated with the company within the pharmaceutical sector. While the text includes standard disclosures regarding a beneficial long position in LEGN and general Seeking Alpha disclaimers, the core financial narrative focuses on BMY's robust earnings beat and upward revision of profit expectations.
📈 BMY stock hit 52-week high of $64.96 on June 28.
💰 Q2 revenue reached $12.97 billion, up 12.9% quarter-over-quarter.
🚀 Non-GAAP EPS rose 39.7% year-over-year to $2.04.
📊 Company raised 2026 diluted EPS guidance to $6.75-$7.
💉 Strong demand drives Opdivo Qvantig and Breyanzi sales.
📈 BMY stock reached a 52-week high of $64.96 on June 28 following Q2 results.
Institutional investors have significantly adjusted their positions in Bristol Myers Squibb (NYSE:BMY) during the first quarter and fourth quarter of recent trading periods. While 44 Wealth Management LLC reduced its stake by 23.9%, trimming holdings to approximately $2.68 million, several major funds increased their exposure. Norges Bank initiated a new position valued at roughly $1.95 billion, while AQR Capital Management grew its stake by 172.6% to hold over $1.39 billion in shares.
Other notable institutional activity includes Bank of New York Mellon raising its holdings by 47.0% and Geode Capital Management increasing its position by 13.1%. Man Group plc also lifted its stake by 280.4% during the second quarter. Collectively, hedge funds and other institutional investors now own approximately 76.41% of the company's outstanding stock, indicating strong continued interest from large-scale capital despite some individual reductions.
The article provides detailed financial metrics for Bristol Myers Squibb, noting a market capitalization of $126.70 billion and a current share price opening at $62.05. The company maintains a dividend yield of 4.1% with an annualized payout of $2.52 per share, supported by a payout ratio of 70.79%. Analyst consensus remains mixed, with an average rating of 'Hold' and a consensus price target of $61.25, though individual targets vary from $54 to $67.
📉 Wealth Management LLC sold shares, holding 44,227 valued at $2.68 million.
📈 Norges Bank added $1.95 billion stake in Q4.
📈 AQR Capital increased holdings by 172.6% to $1.39 billion.
💰 Market cap is $126.70 billion with P/E of 17.43.
👥 Analysts rate 'Hold' with a $61.25 price target.
📉 44 Wealth Management LLC reduced its Bristol Myers Squibb stake by 23.9%, holding 44,227 shares valued at $2.68 million as of the latest filing.
📈 Norges Bank established a new position in BMY worth approximately $1.95 billion during the fourth quarter.
📈 AQR Capital Management increased its holdings by 172.6%, now owning 25,796,905 shares valued at $1.39 billion.
📈 Bank of New York Mellon raised its stake by 47.0% to own 24,495,875 shares worth $1.32 billion.
📈 Geode Capital Management lifted its position by 13.1%, holding 52,638,346 shares valued at $2.84 billion.
📈 Man Group plc increased its stake by 280.4% in the second quarter, owning 7,465,845 shares worth $345 million.
💰 Bristol Myers Squibb has a market cap of $126.70 billion and trades with a P/E ratio of 17.43.
💸 The company announced a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record on July 2nd.
📊 Institutional ownership stands at 76.41%, with the stock trading between a 52-day average of $57.49 and a 200-day average of $58.03.
👥 Analyst sentiment is mixed, with an average rating of 'Hold' and a consensus price target of $61.25.
Bullish Signals
Major investors like Norges Bank increased stakes significantly.
Attractive 4.1% dividend yield with manageable 70.79% payout ratio.
Strong 76.41% institutional ownership signals confidence in long-term prospects.
Risk Factors
Analyst consensus Hold targets $61.25, below recent $62.05 open.
Cantor Fitzgerald neutral target is lower at $54.00.
Weiss Ratings downgraded to hold (c) showing caution.
Bullish Signals
Major institutional investors including Norges Bank, AQR Capital Management, and Bank of New York Mellon have significantly increased their stakes in the company.
The stock offers an attractive 4.1% dividend yield with a consistent payout history and a manageable 70.79% payout ratio.
Strong institutional ownership at 76.41% suggests confidence from large capital managers in the company's long-term prospects.
Risk Factors
Analyst consensus is currently 'Hold' with a price target of $61.25, which is below the recent opening price of $62.05.
Cantor Fitzgerald maintains a neutral rating with a lower price target of $54.00 compared to other analysts.
Weiss Ratings recently downgraded the stock from 'hold (c+)' to 'hold (c)', indicating some caution among rating agencies.
Erste Group Bank analyst H. Engel has lowered its full-year 2027 earnings per share (EPS) forecast for Bristol Myers Squibb to $6.10, down from a previous estimate of $6.12. This adjustment places the company below the broader consensus estimate of $6.34. The report was issued on July 15th, signaling a shift in analyst sentiment regarding future profitability expectations for the biopharmaceutical firm.
Recent market activity shows mixed signals from other major financial institutions. While Bank of America maintained a 'buy' rating despite cutting its price target to $66.00, Cantor Fitzgerald set a lower neutral target at $54.00. The stock currently trades with a consensus 'Hold' rating and a target price of $61.25, trading near its 52-week high of $62.89 but well above its 52-week low of $42.52.
Fundamental performance remains robust based on the latest quarterly results released on April 30th. Bristol Myers Squibb reported EPS of $1.58, beating analyst expectations of $1.42, with revenue reaching $11.49 billion, a 2.6% increase year-over-year. The company maintains strong financial health with a return on equity of 64.87% and a net margin of 15.01%, while offering an annualized dividend yield of 4.2%.
Institutional ownership continues to grow significantly among major asset managers. Vanguard Group, State Street Corp, Geode Capital Management, Norges Bank, and AQR Capital Management all increased their holdings in the fourth quarter. Notably, AQR Capital Management boosted its position by 172.6%, while institutional investors collectively own 76.41% of the company's outstanding shares.
📉 Erste Group cut FY2027 EPS estimate to $6.10 from $6.12.
💰 Q1 2026 EPS hit $1.58, beating the $1.42 consensus.
📈 Revenue reached $11.49 billion, up 2.6% year-over-year.
🏦 AQR Capital raised stake by 172.6% in Q4.
💵 Quarterly dividend of $0.63 yields 4.2% annually.
📉 Erste Group Bank analyst H. Engel cut FY2027 EPS estimates for Bristol Myers Squibb to $6.10 from $6.12.
📊 The stock currently holds a consensus 'Hold' rating with an average target price of $61.25 across major banks.
💰 Q1 2026 results showed strong performance with $1.58 EPS, beating the $1.42 consensus estimate.
📈 Revenue for the quarter reached $11.49 billion, representing a 2.6% year-over-year increase.
🏦 Institutional investors increased stakes in Q4, with AQR Capital Management raising its position by 172.6%.
💵 The company declared a quarterly dividend of $0.63 per share, yielding 4.2% annually to shareholders.
📉 Bank of America lowered its price objective to $66.00 while maintaining a 'buy' rating on the stock.
📉 Cantor Fitzgerald restated a neutral rating with a lower target price of $54.00 for the shares.
🏛️ The firm maintains a strong balance sheet with a debt-to-equity ratio of 2.10 and a quick ratio of 1.28.
🧬 Bristol Myers Squibb focuses its pipeline on oncology, hematology, immunology, and cardiovascular diseases.
Bullish Signals
Q1 EPS $1.58 beat consensus $1.42.
Net margin 15.01% and ROE 64.87%.
Revenue $11.49B up 2.6% year-over-year.
Institutional investors increased holdings in Q4.
AQR stake surged 172.6% to 16M shares.
Dividend yield 4.2% with 70.79% payout.
Risk Factors
Erste Group lowered FY2027 EPS forecast to $6.10.
Cantor Fitzgerald target price of $54.00 below current price.
Bank of America reduced objective from $67.00 to $66.00.
Bullish Signals
Bristol Myers Squibb reported Q1 2026 EPS of $1.58, which significantly topped analyst consensus estimates of $1.42.
The company achieved a net margin of 15.01% and a return on equity of 64.87% during the quarter.
Quarterly revenue of $11.49 billion exceeded expectations of $10.93 billion, showing growth of 2.6% year-over-year.
Major institutional investors including Vanguard Group, State Street Corp, and Geode Capital Management increased their holdings in the fourth quarter.
AQR Capital Management aggressively increased its stake by 172.6%, adding over 16 million shares to its portfolio.
The company offers a substantial annualized dividend yield of 4.2% with a payout ratio of 70.79%.
Risk Factors
Erste Group Bank analyst lowered the FY2027 EPS forecast to $6.10, indicating reduced growth expectations for the coming year.
Cantor Fitzgerald set a neutral rating with a target price of $54.00, which is below the current trading price.
Bank of America reduced its price objective from $67.00 to $66.00 despite maintaining a buy rating.
Aware Super Pty Ltd increased its position in Bristol Myers Squibb (NYSE:BMY) by purchasing 328,003 shares valued at approximately $19.9 million during the first quarter. This move joins a list of other institutional investors, including Swiss RE and various wealth management firms, who have recently established or expanded stakes in the biopharmaceutical company, with hedge funds collectively owning 76.41% of the outstanding stock.
Bristol Myers Squibb's stock opened at $60.47 on Friday, trading against a market capitalization of $123.48 billion and a price-to-earnings ratio of 16.99. The company recently declared a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record as of July 2nd, resulting in an annualized yield of 4.2% with a payout ratio of 70.79%. Technical indicators show the stock trading above its fifty-day moving average but below its 200-day average.
Analyst sentiment remains mixed regarding the company's future prospects. While UBS Group maintained a 'buy' rating and Bank of America lowered its price objective to $66, Cantor Fitzgerald issued a 'neutral' rating with a $54 target. The consensus among eight investment analysts is currently a 'Hold' with an average price target of $61.25. Bristol Myers Squibb continues to focus on its core portfolio in oncology and immune-mediated conditions through small molecules and biologics.
📈 Aware Super bought 328,003 shares worth $19.9 million in Q1.
🏦 Institutional ownership is high at 76.41% with new stakes added.
💰 Quarterly dividend of $0.63 per share payable August 3rd.
📊 Market cap is $123.48 billion with a P/E ratio of 16.99.
🎯 Analyst consensus is 'Hold' with an average price target of $61.25.
📈 Aware Super Pty Ltd acquired a new position of 328,003 shares valued at approximately $19.9 million in the first quarter.
🏦 Institutional ownership remains high at 76.41%, with other firms like Swiss RE and Darwin Wealth Management adding new stakes.
💰 The company declared a quarterly dividend of $0.63 per share, payable on August 3rd to investors of record by July 2nd.
📊 Bristol Myers Squibb trades at a market cap of $123.48 billion with a P/E ratio of 16.99 and a beta of 0.23.
📉 The stock opened at $60.47, trading above its fifty-day moving average of $56.93 but below the 200-day average of $57.76.
🎯 Analyst consensus is currently a 'Hold' with an average price target of $61.25 based on data from MarketBeat.com.
📉 Bank of America reduced its price objective to $66 while maintaining a 'buy' rating in a recent research note.
⚖️ Cantor Fitzgerald reissued a 'neutral' rating with a lower price objective of $54.00 for the biopharmaceutical stock.
🔬 The company focuses on discovering and delivering medicines for serious diseases, specifically in oncology and immune-mediated conditions.
💸 The dividend payout ratio stands at 70.79%, representing an annualized yield of 4.2%.
Bullish Signals
Institutional confidence shown by $19.9 million new position.
Risk Factors
Neutral $54 target below current ~$60 price.
BofA cut target from $67 to $66.
Stock trades below 200-day moving average of $57.76.
Weiss Ratings restated hold (c+) with caution.
Bullish Signals
Aware Super Pty Ltd established a significant new position valued at $19.9 million, indicating institutional confidence in the company's long-term prospects.
The company maintains a strong dividend profile with a 4.2% annualized yield and a payout ratio of 70.79%, providing steady income to shareholders.
UBS Group restated a 'buy' rating on the stock, signaling continued analyst support for Bristol Myers Squibb's strategic direction.
The firm holds a robust balance sheet with a quick ratio of 1.28 and a current ratio of 1.42, ensuring liquidity for ongoing operations.
Risk Factors
Cantor Fitzgerald issued a 'neutral' rating with a price objective of $54.00, which is significantly below the current trading price of approximately $60.
Bank of America reduced its price target from $67.00 to $66.00, suggesting potential downside pressure or a more conservative valuation outlook.
The stock trades below its 200-day moving average of $57.76, indicating some short-term weakness relative to longer-term trends.
Weiss Ratings restated a 'hold (c+)' rating, reflecting cautious sentiment among analysts regarding the company's immediate performance.
Bristol-Myers Squibb (NYSE:BMY) is highlighted as a top-tier cash-rich dividend stock, ranking second on a list of eight such companies. The article notes that corporate cash reserves have reached an all-time high of $4.11 trillion in Q1 2024, driven by strong economic conditions and elevated interest rates, with many corporations earning significant interest income on these holdings.
BMY reported nearly $12 billion in revenue for the third quarter of 2024, an 8.5% increase year-over-year, fueled by growth in its oncology portfolio. The company holds approximately $8 billion in cash and cash equivalents as of the end of the quarter, maintaining a robust balance sheet that supports its status as a solid dividend payer with payouts increased for 18 consecutive years.
Financial metrics show BMY generated $15 billion in operating cash flow and $17.52 billion in levered free cash flow over the trailing twelve months. The stock currently offers a 4.44% dividend yield with a quarterly payout of $0.60 per share. Hedge fund interest has grown, with stakes held by 70 funds totaling over $3.3 billion as of Q3 2024.
Despite its strong fundamentals and cash position, the article suggests that BMY may not offer the highest potential returns compared to AI stocks trading at low valuations. The stock has risen nearly 6% since the start of 2024 following FDA approval for its schizophrenia treatment Cobenfy, though the author maintains a preference for higher-growth sectors.
📈 BMY ranks second among eight recommended cash-rich dividend stocks.
💰 Q3 2024 revenue hit $12 billion, an 8.5% year-over-year increase.
🏦 The company holds approximately $8 billion in cash and equivalents.
💵 Stock offers a 4.44% yield with a $0.60 quarterly payout.
🔍 Hedge fund stakes rose to over $3.3 billion across 70 funds.
📈 Bristol-Myers Squibb (BMY) ranks second on a list of eight cash-rich dividend stocks recommended for investment.
💰 The company reported $12 billion in Q3 2024 revenue, representing an 8.5% increase from the prior year.
🏦 BMY holds approximately $8 billion in cash and cash equivalents as of the end of the third quarter.
💵 The stock offers a 4.44% dividend yield with a quarterly payout of $0.60 per share.
📊 Over the trailing twelve months, operating cash flow reached $15 billion and levered free cash flow hit $17.52 billion.
🔍 Hedge fund ownership increased to 70 funds in Q3 2024, with collective stakes valued at over $3.3 billion.
💊 The FDA approved Cobenfy for schizophrenia treatment in September, contributing to a nearly 6% stock surge since the start of 2024.
📉 Oncology portfolio expansion and efficient operational management drove the strong third-quarter financial performance.
🧠 Analysts note that while BMY is solid, AI stocks may offer higher returns within shorter time frames.
📅 The article was published on December 18, 2024, analyzing data through mid-December 2023 and Q3 2024.
Bullish Signals
Revenue up 8.5% to $12B in Q3 2024.
$8B cash position as of late Q3 2024.
Dividend increased for 18 consecutive years.
Levered free cash flow hit $17.52 billion.
Hedge fund stakes grew to 70 funds totaling $3.3B.
Risk Factors
AI stocks may outperform BMY faster, limiting relative upside.
BMY ranks second for cash-rich dividends, implying better alternatives exist.
Bullish Signals
BMY reported an 8.5% year-over-year revenue increase to nearly $12 billion in the third quarter of 2024.
The company maintains a strong cash position with approximately $8 billion in cash and cash equivalents as of late Q3 2024.
BMY has increased its dividend payouts for 18 consecutive years, demonstrating a long history of shareholder returns.
Levered free cash flow reached $17.52 billion over the trailing twelve months, providing ample flexibility for future dividends or acquisitions.
Hedge fund sentiment is positive, with tracked stakes growing from 61 to 70 funds in Q3 2024, totaling over $3.3 billion.
The stock has gained nearly 6% since the start of 2024 following FDA approval for its schizophrenia drug Cobenfy.
Risk Factors
The article suggests that AI stocks may offer higher returns than BMY within a shorter time frame, potentially limiting relative upside.
BMY ranks second on the author's list of cash-rich dividend stocks, implying other companies in the same category might be viewed as superior.
Hudson Edge Investment Partners Inc. reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 17.7% during the first quarter, selling 29,888 shares to hold a remaining position of 138,879 shares valued at $8.42 million. This reduction brings BMY to 1.2% of Hudson Edge's total holdings, marking it as the firm's 12th largest position according to recent SEC 13F filings.
Conversely, several major institutional investors increased their stakes in Bristol Myers Squibb during the fourth quarter. Vanguard Group boosted its position by 1.4% to own nearly 199 million shares worth over $10.7 billion, while State Street Corp and Geode Capital Management also added significant holdings. Norges Bank initiated a new stake valued at approximately $1.95 billion, and AQR Capital Management surged its position by 172.6%.
The article details Bristol Myers Squibb's current financial metrics, noting a market capitalization of $118.54 billion and a dividend yield of 4.3%. The company recently declared a quarterly dividend of $0.63 per share payable on August 3rd for shareholders of record on July 2nd. Analyst consensus remains mixed with a 'Hold' rating and a price target of $61.31, though recent upgrades from Wall Street Zen and UBS suggest continued institutional interest.
Bristol Myers Squibb operates as a global biopharmaceutical company headquartered in Princeton, New Jersey, focusing on oncology, hematology, immunology, and cardiovascular disease. The firm's portfolio emphasizes cancer and immune-mediated conditions through both small molecules and biologics. Institutional ownership stands at 76.41%, reflecting broad market confidence despite the recent reduction by Hudson Edge Investment Partners.
📉 Hudson Edge sold 29,888 shares, retaining $8.42 million stake.
📈 Vanguard owns 198.7M shares valued at $10.7 billion.
🇳🇴 Norges Bank started new $1.95 billion position in Q4.
💰 BMY pays $0.63 dividend with 4.3% yield ex-July 2nd.
📊 Market cap is $118.54B with PE ratio of 16.31.
📉 Hudson Edge Investment Partners Inc. reduced its Bristol Myers Squibb stake by 17.7% in Q1, selling 29,888 shares to retain a position worth $8.42 million.
📈 Vanguard Group increased its BMY holdings by 1.4% in Q4, now owning 198,727,768 shares valued at approximately $10.7 billion.
📈 State Street Corp and Geode Capital Management also boosted their positions by 1.4% and 13.1% respectively during the fourth quarter.
🇳🇴 Norges Bank initiated a new stake in Bristol Myers Squibb valued at roughly $1.95 billion in Q4.
📈 AQR Capital Management significantly increased its position by 172.6%, acquiring an additional 16.3 million shares worth $1.39 billion.
💰 BMY declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 2nd and a yield of 4.3%.
📊 The company trades at a market cap of $118.54 billion with a PE ratio of 16.31 and a beta of 0.23.
📈 Wall Street Zen upgraded BMY to a 'strong-buy' rating, while UBS reissued a 'buy' rating on the stock.
🎯 Analyst consensus remains 'Hold' with a price target of $61.31 based on ratings from eight buy, ten hold, and one sell analysts.
💊 Bristol Myers Squibb focuses its R&D and commercialization efforts on oncology, hematology, immunology, and cardiovascular diseases.
Bullish Signals
Major institutions increased stakes in Q4.
Strong 4.3% dividend yield with 70.79% payout ratio.
Wall Street Zen upgraded to strong-buy.
Guggenheim price target set at $72.00.
Institutional ownership stands at 76.41%.
Risk Factors
Major investor reduced stake by 17.7% in Q1.
Analyst price target of $61.31 is below current range.
One analyst assigned a 'Sell' rating.
Bullish Signals
Major institutional investors including Vanguard, State Street, Geode Capital, Norges Bank, and AQR Capital Management all increased their stakes in the fourth quarter.
The company maintains a strong dividend yield of 4.3% with a payout ratio of 70.79%, providing consistent income to shareholders.
Wall Street Zen upgraded the stock from 'buy' to 'strong-buy', and UBS reissued a 'buy' rating, indicating analyst confidence.
Guggenheim reiterated a 'buy' rating and set a price target of $72.00, which is above the current trading price.
Institutional ownership remains high at 76.41%, suggesting broad support from large asset managers.
Risk Factors
Hudson Edge Investment Partners Inc. reduced its stake by 17.7% in Q1, signaling a decrease in interest from this specific investor.
The consensus analyst rating is 'Hold' with a price target of $61.31, which is below the current stock price of approximately $58.05 to $62.89 range depending on recent movement.
One analyst has assigned a 'Sell' rating to the company, contributing to a mixed sentiment profile.
Fjarde AP Fonden increased its stake in Bristol Myers Squibb (NYSE:BMY) by 21.5% during the first quarter, purchasing an additional 105,200 shares to hold a total of 595,006 shares valued at approximately $36 million. This move aligns with other major institutional investors who also expanded their positions in the biopharmaceutical giant during the fourth quarter, including Vanguard Group, State Street Corp, Geode Capital Management, Norges Bank, and AQR Capital Management.
Institutional ownership of Bristol Myers Squibb stands at 76.41%, reflecting continued confidence from large asset managers. The company currently trades with a market capitalization of $118.54 billion and a price-to-earnings ratio of 16.31. Analyst consensus ratings remain mixed, with eight buy ratings, ten hold ratings, and one sell rating, resulting in a consensus target price of $61.31.
Bristol Myers Squibb recently announced a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record as of July 2nd. This dividend represents an annualized yield of 4.3% with a payout ratio of 70.79%. The stock has seen recent analyst attention, including a price target increase from HSBC and a strong-buy upgrade from Wall Street Zen.
📈 Fjarde AP Fonden added 105,200 shares, holding 595,006 total.
🏦 Vanguard Group owns 198.7M shares worth over $10.7 billion.
💰 Norges Bank started a new $1.95 billion position in Q4.
🚀 AQR Capital boosted stake by 172.6% to 25.8 million shares.
📉 Institutional investors hold 76.41% of Bristol Myers Squibb stock.
📈 Fjarde AP Fonden increased its BMY stake by 21.5% in Q1, adding 105,200 shares to a total holding of 595,006 shares.
🏦 Vanguard Group lifted its position by 1.4% in Q4, now owning 198.7 million shares worth over $10.7 billion.
📊 State Street Corp grew its BMY holdings by 1.4% in the fourth quarter to a total value of $5.28 billion.
🚀 Geode Capital Management LLC increased its stake by 13.1% in Q4, acquiring an additional 6 million shares.
💰 Norges Bank initiated a new position in BMY valued at approximately $1.95 billion during the fourth quarter.
📈 AQR Capital Management significantly boosted its exposure, lifting its position by 172.6% to own 25.8 million shares.
📉 Institutional investors collectively hold 76.41% of Bristol Myers Squibb's outstanding stock.
💵 The company declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 2nd.
🎯 HSBC raised its price target for BMY from $53.00 to $60.00 while maintaining a hold rating.
⭐ Wall Street Zen upgraded Bristol Myers Squibb from a buy to a strong-buy rating in late June.
📊 Guggenheim reiterated a buy rating and set a price target of $72.00 for the biopharmaceutical stock.
📉 The consensus analyst rating is hold with a mean price target of $61.31 according to MarketBeat.
Bullish Signals
Major institutions increased stakes including Fjarde AP Fonden and Vanguard.
Stock offers 4.3% dividend yield with 70.79% payout ratio.
HSBC raised price objective from $53.00 to $60.00.
Wall Street Zen upgraded stock to strong-buy rating.
Guggenheim maintains buy rating with $72.00 price target.
Risk Factors
Consensus hold rating suggests limited immediate upside potential.
One of eleven analyst ratings is a sell.
Bullish Signals
Major institutional investors including Fjarde AP Fonden, Vanguard, State Street, Geode Capital, Norges Bank, and AQR Capital Management all increased their stakes in the company during recent quarters.
The stock offers a dividend yield of 4.3% with a payout ratio of 70.79%, providing income to shareholders.
HSBC raised its price objective from $53.00 to $60.00, indicating improved valuation expectations.
Wall Street Zen upgraded the stock to a strong-buy rating, signaling confidence in future performance.
Guggenheim maintains a buy rating with a specific price target of $72.00.
Risk Factors
The consensus analyst rating is hold, suggesting that while the company is stable, there may be limited immediate upside potential according to Wall Street analysts.
Only one sell rating exists among eleven total ratings, indicating some analysts remain cautious about the stock's near-term prospects.
Bristol-Myers Squibb (NYSE:BMY) is approaching its ex-dividend date of July 2nd, with the dividend payment scheduled for August 3rd. The upcoming quarterly dividend is set at US$0.63 per share, following a total annual distribution of US$2.52 over the last 12 months. This results in a trailing yield of approximately 4.4% based on the current share price of US$57.52.
The company demonstrates dividend sustainability by covering its payouts with both earnings and free cash flow. Last year, Bristol-Myers Squibb paid out roughly 70% of its earnings and only 43% of its free cash flow toward dividends. Historical data shows steady earnings per share growth averaging 9.3% over the last five years, while dividend increases have averaged 5.5% annually over the past decade.
Analysts note that while the company effectively rewards shareholders with a sustainable dividend, it is unlikely to reinvest heavily in business expansion due to the high payout ratio relative to earnings. The stock is viewed as an 'okay' investment for income but not necessarily a standout growth opportunity without significant changes in earnings or valuation.
📅 Ex-dividend July 2nd; $0.63 payable August 3rd.
💰 4.4% yield on current price of $57.52.
📈 EPS grew 9.3% annually over last five years.
💵 Dividends covered by 70% of earnings and 43% of FCF.
📉 Average dividend increase of 5.5% per year for decade.
📅 BMY stock will trade ex-dividend on July 2nd, with the US$0.63 dividend payable on August 3rd.
💰 The trailing dividend yield is 4.4% based on a current share price of US$57.52.
📈 Earnings per share have grown by an average of 9.3% over the last five years.
💵 Dividends are covered by 70% of earnings and only 43% of free cash flow from the prior year.
📉 The company has increased its dividend by approximately 5.5% annually on average over the last decade.
⚠️ High payout ratio relative to earnings suggests limited capacity for heavy business reinvestment.
Bullish Signals
Upcoming dividend of US$0.63 offers 4.4% trailing yield.
Dividends covered by profits (70%) and free cash flow (43%).
EPS grew 9.3% annually over last five years.
Dividends increased 5.5% annually over past 10 years.
Risk Factors
High payout ratio limits business growth reinvestment.
Janney Montgomery Scott LLC increased its stake in Bristol Myers Squibb (NYSE:BMY) by 6.8% in the first quarter, purchasing 49,310 shares to bring total holdings to 770,244 shares valued at approximately $46.7 million. Other institutional investors also adjusted positions, with Horizon Bancorp increasing its stake by 22.1% and several wealth management firms adding new or increased positions, while company insiders own a negligible 0.05% of the stock.
Bristol Myers Squibb reported better-than-expected quarterly financial results, posting earnings per share (EPS) of $1.58 against a consensus estimate of $1.42 and revenue of $11.49 billion versus an expected $10.93 billion. The company achieved a net margin of 15.01% and a return on equity of 64.87%, with revenue growing 2.6% year-over-year. Additionally, the firm declared a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record on July 2nd.
Analyst sentiment remains mixed but generally positive regarding the company's fundamentals. UBS restated a 'buy' rating, Wall Street Zen upgraded the stock to 'strong-buy', and HSBC raised its price objective from $53.00 to $60.00, though Bank of America lowered its target to $67.00. The consensus analyst rating is currently 'Hold' with an average price target of $61.31, while the stock trades at a P/E ratio of 16.14 and a market capitalization of $117.31 billion.
📈 Janney Montgomery Scott bought 49,310 BMY shares for $46.7M.
💰 Bristol Myers Squibb beat earnings with $1.58 EPS and $11.49B revenue.
📊 Company reported 15.01% net margin and 64.87% return on equity.
💵 Quarterly dividend declared at $0.63 per share for 4.4% yield.
📉 EVP David V. Elkins sold 30,000 shares, reducing position by 15.85%.
📈 Janney Montgomery Scott LLC increased its BMY stake by 6.8% in Q1, buying 49,310 shares for a total holding value of $46.7 million.
💰 Bristol Myers Squibb beat earnings expectations with $1.58 EPS and $11.49 billion revenue, surpassing analyst consensus estimates.
📊 The company reported strong profitability metrics including a 15.01% net margin and a 64.87% return on equity.
💵 A quarterly dividend of $0.63 per share was declared, offering a yield of 4.4% to shareholders.
📉 EVP David V. Elkins sold 30,000 shares in early April, reducing his personal position by 15.85%.
🏦 Institutional ownership remains high at 76.41%, with multiple firms like Horizon Bancorp and Cornerstone Wealth increasing stakes.
📝 Analyst ratings are mixed; UBS and Wall Street Zen maintain or upgrade 'buy' ratings, while Bank of America lowered its price target.
🎯 The consensus analyst price target is $61.31, with the stock currently trading at a P/E ratio of 16.14.
📈 Revenue grew 2.6% year-over-year, demonstrating continued top-line growth in the biopharmaceutical sector.
Bullish Signals
EPS beat estimates at $1.58 vs $1.42 consensus.
Revenue hit $11.49B, up 2.6% year-over-year.
Institutional confidence rises as Janney adds 6.8% position.
Wall Street Zen upgrades rating to strong-buy.
HSBC raises price target from $53 to $60.
Quarterly dividend of $0.63 offers 4.4% yield.
Risk Factors
David V. Elkins sold 30,000 shares, reducing stake by 15.85%.
Bank of America lowered price objective from $68.00 to $67.00.
Citigroup reissued neutral rating on the stock.
Consensus analyst rating is Hold with limited upside potential.
Bullish Signals
Bristol Myers Squibb reported earnings per share of $1.58, which beat analyst consensus estimates of $1.42 by $0.16.
The company generated revenue of $11.49 billion, exceeding the expected $10.93 billion and showing a 2.6% year-over-year increase.
Janney Montgomery Scott LLC increased its position by 6.8%, signaling institutional confidence in the stock's prospects.
Wall Street Zen upgraded its rating on BMY from 'buy' to 'strong-buy', reflecting improved analyst sentiment.
HSBC raised its price objective for Bristol Myers Squibb from $53.00 to $60.00, indicating a bullish outlook on valuation.
The company declared a quarterly dividend of $0.63 per share, providing a 4.4% yield to investors.
Risk Factors
EVP David V. Elkins sold 30,000 shares in early April, reducing his personal stake by 15.85%.
Bank of America lowered its price objective for Bristol Myers Squibb from $68.00 to $67.00.
Citigroup reissued a 'neutral' rating on the stock, contributing to a mixed analyst consensus.
The consensus analyst rating is currently 'Hold', suggesting some analysts see limited upside potential at current levels.
Wall Street Zen upgraded Bristol Myers Squibb (NYSE:BMY) to a 'strong-buy' rating, joining a mixed consensus of eight buy ratings, ten holds, and one sell. The stock currently trades with an average analyst target price of $61.31, reflecting varied sentiment among major institutions including recent downgrades from Bank of America and reaffirmations from Citigroup.
The company reported strong quarterly financial results for the quarter ended April 30th, beating consensus estimates significantly. Bristol Myers Squibb generated revenue of $11.49 billion, surpassing analyst expectations of $10.93 billion, while posting earnings per share (EPS) of $1.58 against a consensus of $1.42. The firm achieved a net margin of 15.01% and a return on equity of 64.87%, with revenue growing 2.6% year-over-year.
Looking ahead, Bristol Myers Squibb has set full-year 2026 EPS guidance between $6.05 and $6.35, which aligns closely with the average analyst prediction of $6.32 for the current fiscal year. Recent insider activity includes a notable sale by EVP David V. Elkins, who reduced his holdings by 15.85% in April, while several hedge funds have increased their stakes in the first quarter.
📈 Wall Street Zen upgraded stock to 'strong-buy' rating.
💰 Q1 EPS beat estimates at $1.58 per share.
📊 Revenue grew 2.6% YoY to reach $11.49 billion.
🔮 FY 2026 EPS guidance aligns with analyst consensus.
🏦 Hedge funds increased positions while EVP sold shares.
📈 Wall Street Zen upgraded Bristol Myers Squibb to a 'strong-buy' rating, adding to eight existing buy ratings from major analysts.
💰 The company reported Q1 EPS of $1.58, beating the consensus estimate of $1.42 by $0.16.
📊 Revenue reached $11.49 billion for the quarter, exceeding analyst estimates of $10.93 billion and growing 2.6% year-over-year.
🎯 Bristol Myers Squibb achieved a net margin of 15.01% and a return on equity of 64.87% during the reported period.
🔮 The company provided FY 2026 EPS guidance ranging from $6.05 to $6.35, aligning with analyst consensus of $6.32.
📉 EVP David V. Elkins sold 30,000 shares in April for a total transaction value of $1,850,100.
🏦 Hedge fund activity shows mixed signals, with NewEdge Advisors increasing its position by 12.9% while Basecamp Wealth Advisors lifted holdings by 13.8%.
📉 The current consensus analyst rating for the stock remains 'Hold' with a target price of $61.31.
💊 Bristol Myers Squibb focuses its portfolio on oncology, hematology, immunology, and cardiovascular disease through small molecules and biologics.
Bullish Signals
EPS beat at $1.58 vs $1.42 estimate.
Revenue hit $11.49B above $10.93B forecast.
Net margin reached 15.01% with ROE of 64.87%.
Upgraded to 'strong-buy' by Wall Street Zen.
FY 2026 EPS guidance aligns at $6.05-$6.35.
Risk Factors
Bank of America lowered price target from $68.00 to $67.00.
EVP David V. Elkins reduced ownership by 15.85% in April.
Bullish Signals
Bristol Myers Squibb beat quarterly earnings expectations with EPS of $1.58 versus the consensus estimate of $1.42.
Revenue of $11.49 billion exceeded analyst forecasts of $10.93 billion, demonstrating strong commercial performance.
The company delivered a robust net margin of 15.01% and a high return on equity of 64.87%.
Wall Street Zen upgraded the stock to 'strong-buy', signaling increased institutional confidence in the company's prospects.
FY 2026 guidance of $6.05-$6.35 EPS aligns well with analyst consensus, suggesting stable future expectations.
Risk Factors
Bank of America lowered its price target from $68.00 to $67.00, indicating some caution among analysts.
EVP David V. Elkins sold a significant portion of his holdings, reducing ownership by 15.85% in April.
Bristol-Myers Squibb (BMY) is currently trading at $54.70, reflecting a recent 30-day decline of 8.01% despite a 22.41% total shareholder return over the past year. The company has declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026, offering a yield of approximately 4.6%.
Analysts at Simply Wall St estimate BMY's fair value at $62.96, suggesting the stock is undervalued by roughly 13%. This valuation gap is attributed to a robust late-stage pipeline, strategic partnerships with entities like BioNTech and Philochem, and potential for label expansions that could offset upcoming patent expiries for major brands such as Eliquis and Opdivo.
Despite the bullish fair value narrative, the stock faces mixed signals regarding valuation metrics. The current P/E ratio of 15.4x is slightly above the US pharmaceuticals industry average of 14.9x but below a calculated fair ratio of 18.6x and peer averages of 21.7x. Investors must weigh these potential upside drivers against significant risks including patent cliffs, pricing pressure in the core U.S. market, and shifting revenue mix dynamics.
📈 BMY trades at $54.70 with a 22.41% one-year return.
💰 Quarterly dividend of $0.63 yields approximately 4.6%.
📊 Analysts estimate fair value of $62.96, implying 13% undervaluation.
🔬 Partnerships expand pipeline to offset patent expiries for Eliquis and Opdivo.
⚠️ Risks include patent cliffs and U.S. pricing pressure.
📈 BMY stock is trading at $54.70 with a recent 30-day return of -8.01% but a 1-year total shareholder return of 22.41%.
💰 The company declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, yielding approximately 4.6%.
📊 Analysts estimate a fair value of $62.96, implying the stock is undervalued by roughly 13% based on discounted cash flow models.
🔬 Strategic partnerships with BioNTech and Philochem aim to expand pipeline breadth and offset patent expiries for key drugs like Eliquis and Opdivo.
⚖️ The current P/E ratio of 15.4x sits between the industry average of 14.9x and a fair peer-adjusted ratio of 18.6x.
⚠️ Significant risks include patent cliffs for major revenue drivers and ongoing pressure on pricing and margins in the U.S. market.
Bullish Signals
4.6% dividend yield with $0.63 quarterly payout.
Risk Factors
Patent cliffs for Eliquis and Opdivo pose risks.
P/E ratio of 15.4x exceeds industry average of 14.9x.
Bullish Signals
The company offers a 4.6% dividend yield with a declared quarterly payout of $0.63 per share.
Analyst fair value models suggest BMY is undervalued by approximately 13% relative to a target price of $62.96.
A robust late-stage pipeline and strategic partnerships are expected to support top-line growth and offset patent expiries.
Risk Factors
The stock faces meaningful risks from patent cliffs associated with key drugs like Eliquis and Opdivo.
Valuation metrics show mixed signals, with the current P/E ratio of 15.4x exceeding the industry average of 14.9x.
Corient Private Wealth LLC increased its stake in Bristol Myers Squibb (NYSE:BMY) by 7.5% during the fourth quarter, acquiring an additional 33,958 shares to hold a total of 489,348 shares valued at $26.4 million. Several other institutional investors also adjusted their positions, including Swiss RE Ltd., Darwin Wealth Management LLC, and Physician Wealth Advisors Inc., which increased its stake by 73.5%. Collectively, institutional investors own 76.41% of the company's outstanding stock.
Analyst sentiment remains mixed but generally positive, with a consensus rating of 'Hold' and an average price target of $61.31. Major firms like UBS Group and Guggenheim maintain 'Buy' ratings, while HSBC raised its price target to $60.00. Conversely, Wall Street Zen downgraded the stock from 'strong-buy' to 'buy', and Bank of America lowered its price objective to $67.00. The company recently announced a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record as of July 2nd.
Financial metrics indicate Bristol Myers Squibb has a market capitalization of $111.62 billion and a P/E ratio of 15.35. The stock currently trades at $54.66, sitting below its 50-day moving average of $57.25 but above its 52-week low of $42.52. Key financial ratios include a current ratio of 1.42, a quick ratio of 1.28, and a debt-to-equity ratio of 2.10. EVP David V. Elkins sold 30,000 shares in April, reducing his personal holding by 15.85%.
Bristol-Myers Squibb (BMY) shares are trading at $54.70, reflecting a recent 30-day decline of 8.01% despite a 22.41% total shareholder return over the past year. The company recently declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026, offering a yield of approximately 4.6%.
Analysts at Simply Wall St estimate the stock's fair value at $62.96, suggesting it is undervalued by roughly 13%. This valuation gap is attributed to a robust late-stage pipeline, strategic partnerships with entities like BioNTech and Philochem, and potential for label expansions that could offset upcoming patent expiries for major brands such as Eliquis and Opdivo.
Despite the bullish fair value estimate, the stock presents mixed signals regarding valuation metrics. The current P/E ratio of 15.4x sits slightly above the US pharmaceuticals industry average of 14.9x but remains below a calculated fair ratio of 18.6x and peer averages of 21.7x. Investors must weigh these potential upside drivers against significant risks including patent cliffs, pricing pressure in the core U.S. market, and shifting revenue mix dynamics.
📈 BMY shares trade at $54.70 with a 1-year return of 22.41%.
💰 Quarterly dividend is $0.63 per share yielding approximately 4.6%.
🎯 Analysts estimate fair value of $62.96, implying roughly 13% undervaluation.
🔬 Strategic partnerships aim to offset patent expiries for key drugs.
⚠️ Risks include patent cliffs and pressure on U.S. pricing margins.
📈 Bristol-Myers Squibb (BMY) shares are trading at $54.70 with a recent 30-day return of -8.01% but a 1-year total shareholder return of 22.41%.
💰 The company declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026.
📊 The stock offers a current dividend yield of approximately 4.6% based on the latest share price.
🎯 Analysts estimate a fair value of $62.96, implying the stock is undervalued by roughly 13% or an intrinsic discount of 54.52%.
🔬 The company's late-stage pipeline and strategic partnerships with BioNTech and Philochem aim to offset patent expiries for key drugs like Eliquis and Opdivo.
⚖️ The current P/E ratio of 15.4x is slightly above the industry average of 14.9x but below a fair ratio of 18.6x and peer averages of 21.7x.
⚠️ Significant risks include patent cliffs for major brands, pressure on pricing and margins in the core U.S. market, and potential shifts in revenue mix.
Bullish Signals
Undervalued by 13% with fair value of $62.96.
Robust pipeline supports future regulatory approvals and label expansions.
Solid 4.6% dividend yield with quarterly payout of $0.63.
Delivered 22.41% total shareholder return over past year.
Risk Factors
Patent cliffs for Eliquis and Opdivo pose meaningful risks.
P/E ratio of 15.4x exceeds industry average of 14.9x.
Bullish Signals
The stock is estimated to be undervalued by approximately 13% with a fair value of $62.96 compared to the current price of $54.70.
A robust late-stage pipeline and strategic partnerships are expected to support future regulatory approvals and label expansions, helping offset patent expiries.
The company offers a solid 4.6% dividend yield with a declared quarterly payout of $0.63 per share.
The stock has delivered a strong 22.41% total shareholder return over the past year despite recent cooling momentum.
Risk Factors
The company faces meaningful risks from patent cliffs associated with key drugs like Eliquis and Opdivo.
Valuation metrics show mixed signals, with the current P/E ratio of 15.4x sitting above the industry average of 14.9x.
Bristol-Myers Squibb (BMY) stock is currently trading at $56.24, reflecting a mixed performance with a year-to-date return of 5.2% and a recent 90-day decline of 5.81%. The company has recently expanded its kidney cancer trial, the ROSETTA RCC-208 study, through a clinical collaboration with Arcus Biosciences to add new casdatifan arms.
Analysts project that BMY's revenue will decrease by 6.2% annually over the next three years, while profit margins are expected to improve significantly from 15.0% today to 21.5% in three years. Based on these assumptions regarding earnings paths and future multiples, a popular valuation narrative suggests a fair value of $62.96, indicating the stock is undervalued by approximately 10.7%.
Despite the optimistic valuation outlook, the company faces headwinds including upcoming patent expiries on key drugs and the risk that new launches or pipeline assets may underperform expectations. The current P/E ratio of 15.8x sits between the US pharmaceutical industry average of 15.1x and peer group average of 22.3x, suggesting a complex valuation landscape with both risks and opportunities.
🔬 Bristol-Myers Squibb expands kidney cancer trial with Arcus Biosciences.
💰 Stock trades at $56.24 with 4.5% dividend yield and value score of 4.
📉 Analysts forecast annual revenue decreases of 6.2% over next three years.
📈 Profit margins projected to rise from 15.0% to 21.5% in three years.
💵 Fair value estimated at $62.96, implying 10.7% undervaluation.
🔬 Bristol-Myers Squibb expanded its kidney cancer trial (ROSETTA RCC-208) via a collaboration with Arcus Biosciences to include new casdatifan arms.
💰 The stock trades at $56.24, offering a 4.5% dividend yield and a value score of 4.
📉 Analysts forecast annual revenue decreases of 6.2% over the next three years.
📈 Profit margins are projected to rise from 15.0% currently to 21.5% in three years.
💵 A widely followed valuation model estimates a fair value of $62.96, implying a 10.7% undervaluation.
⚠️ The company faces risks from upcoming patent expiries on key drugs and potential underperformance of new launches.
📊 The current P/E ratio of 15.8x is higher than the industry average (15.1x) but lower than peers (22.3x).
Bullish Signals
Clinical collaboration expands kidney cancer trial pipeline.
Profit margins forecast to rise from 15.0% to 21.5%.
Undervalued by 10.7% with fair value target of $62.96.
Attractive 4.5% dividend yield provides income support.
Risk Factors
Revenue projected to drop 6.2% annually for three years.
Key drug patents face imminent expiration pressures.
New launches may underperform market expectations.
Bullish Signals
The company has secured a clinical collaboration with Arcus Biosciences to expand its kidney cancer trial, signaling continued pipeline development.
Analysts forecast a significant improvement in profit margins, rising from 15.0% to 21.5% over the next three years.
Valuation models suggest the stock is undervalued by 10.7% with a fair value target of $62.96 versus the current price of $56.24.
The stock offers an attractive 4.5% dividend yield, providing income support for investors.
Risk Factors
Analysts project that revenue will decrease by 6.2% annually over the next three years.
The company faces real pressure from upcoming patent expiries on its key drugs.
There is a risk that newer launches and pipeline assets could underperform market expectations.
Bristol-Myers Squibb's growth portfolio has surpassed its legacy business in revenue for the first time during Q1 2026, challenging the prevailing market narrative that the company is a "melting ice cube" solely reliant on declining Revlimid and Eliquis sales. The article identifies four specific near-term catalysts within the pipeline—iberdomide, mezigdomide, milvexian, and Cobenfy—that could drive a stock re-rating within seven months of the report's publication.
Valuation analysis suggests the stock is mispriced relative to its fundamentals; even under bearish consensus forecasts, a discounted cash flow (DCF) model supports a target price of $68.5 per share, which represents approximately 20% upside from current levels with downside protection. The company currently trades at a 9x forward earnings multiple and offers a 4.35% dividend yield, positioning it as a bridge to future growth rather than facing an immediate cliff in revenue generation.
📉 Legacy revenue fears persist as Growth Portfolio surpasses Legacy in Q1 2026.
💊 Four pipeline catalysts could force a stock re-rating within seven months.
📈 DCF model supports $68.5 valuation, offering 20% upside with downside protection.
📉 Bristol-Myers Squibb (BMY) is currently viewed by the market as a "melting ice cube" due to fears that its legacy revenue stream is collapsing.
📊 The company's Growth Portfolio has officially surpassed its Legacy Portfolio in terms of revenue for Q1 2026.
💊 Four near-term pipeline catalysts are identified: iberdomide, mezigdomide, milvexian, and Cobenfy.
⏳ These four new drugs could potentially force a stock re-rating within the next seven months.
📈 Even under bearish consensus forecasts, a Discounted Cash Flow (DCF) model supports a valuation of $68.5 per share.
💰 This supported valuation represents approximately 20% upside from current price levels with downside protection.
📉 BMY is trading at a 9x forward earnings multiple and offers a dividend yield of 4.35%.
🛡️ The investment thesis suggests the stock provides free pipeline optionality rather than facing a cliff after Eliquis.
🧬 Revlimid has fallen off its peak, leading to market concerns that Eliquis will be the next major revenue driver.
📊 The author utilizes a data analytics and SQL background to analyze market trends and patterns for this article.
🤝 The author discloses no current stock positions or plans to initiate positions in the mentioned companies within 72 hours.
⚠️ Seeking Alpha notes that past performance does not guarantee future results and this is not investment advice.
Four near-term catalysts like iberdomide could drive re-rating within seven months.
Dow Jones DCF model supports $68.5/share valuation, 20% above current levels.
BMY offers downside protection with 9x forward earnings and 4.35% yield.
Company provides pipeline optionality and financial bridge beyond Eliquis.
Risk Factors
Three-year Revlimid fear creates bearish sentiment for Eliquis.
Stock mispriced as melting ice cube despite Q1 2026 growth.
$68.5 valuation relies on bearish forecasts and decline risks.
Future beyond Eliquis is a bridge, not a cliff.
Reliance on four catalysts implies lack of organic growth.
Bullish Signals
Bristol Myers Squibb's Growth Portfolio revenues surpassed Legacy revenues in Q1 2026, signaling a successful transition away from reliance on Revlimid.
The company has four near-term pipeline catalysts including iberdomide, mezigdomide, milvexian, and Cobenfy that could drive a stock re-rating within seven months.
Even using bearish consensus forecasts, the discounted cash flow (DCF) model supports a $68.5/share valuation, which is approximately 20% above current levels.
BMY offers downside protection with a 9x forward earnings multiple and a 4.35% dividend yield.
The company provides free pipeline optionality and a financial bridge beyond its key drug Eliquis, rather than facing a cliff.
Risk Factors
The market narrative has been dominated for three years by the fear that Revlimid fell off a cliff, creating a bearish sentiment that Eliquis will be the next major revenue driver.
Despite the growth portfolio surpassing legacy revenues in Q1 2026, the article explicitly states the stock is 'mispriced as a melting ice cube', indicating significant underlying fragility and potential value erosion.
The valuation support of $68.5/share relies on bearish consensus forecasts, suggesting that even under pessimistic assumptions, the market may be undervaluing the risk of further declines.
The company's future beyond Eliquis is described as a 'bridge' rather than a 'cliff', implying uncertainty and potential instability in long-term revenue sustainability.
The reliance on four near-term catalysts (iberdomide, mezigdomide, milvexian, and Cobenfy) to force a re-rating within seven months suggests the current business model lacks sufficient organic growth drivers without these specific bets.
BioNTech and Bristol Myers Squibb have announced encouraging interim Phase 2 data from the global ROSETTA Lung-02 clinical trial for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator. The combination of pumitamig with chemotherapy demonstrated robust antitumor activity in patients with previously untreated advanced non-small cell lung cancer (NSCLC) across all evaluated dose levels and PD-L1 expression subtypes. At the interim analysis with an April 13, 2026 data cut-off, treatment showed high efficacy regardless of tumor subtype or programmed death-ligand 1 status.
Specifically, among response-evaluable patients, pumitamig plus chemotherapy achieved a confirmed objective response rate (cORR) of 57.1% in non-squamous NSCLC and 68.4% in squamous NSCLC at the interim analysis. Higher response rates were observed at the lower dose level, with a cORR of 63.6% for non-squamous NSCLC and 72.7% for squamous NSCLC. The efficacy was consistent across patients with less than 1%, between 1-49%, and greater than or equal to 50% PD-L1 tumor proportion score (TPS), reaching 100% response in the TPS ≥ 50 group at the lower dose. Furthermore, the treatment demonstrated a disease control rate of 100% and showed a manageable safety profile with Grade 3 treatment-related adverse events reported in 23.3% of patients attributed to pumitamig, leading to discontinuation in only 9.3% of cases.
The companies are advancing a comprehensive global Phase 3 development program for pumitamig in NSCLC following these positive results. In addition to the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, two additional global Phase 3 trials are underway, including ROSETTA Lung-201 comparing pumitamig to durvalumab following concurrent chemoradiation in unresectable stage III NSCLC and ROSETTA Lung-202 evaluating pumitamig against pembrolizumab as a first-line treatment for advanced PD-L1 ≥ 50% NSCLC. These results support the continued investigation of pumitamig's potential to set a new standard of care by enhancing anti-tumor responses in one of oncology's most challenging indications.
📈 Interim Phase 2 data shows robust activity with up to 72.7% response in squamous NSCLC.
🎯 High efficacy observed across all PD-L1 subgroups including low expression patients (TPS < 1%).
💊 Drug maintains manageable safety with only 9.3% discontinuation and limited severe adverse events.
🌍 Data presented at 2026 ASCO based on April 2026 cut-off for global Phase 3 advancement.
🔄 Multiple pivotal trials enrolling to compare pumitamig against standard-of-care immunotherapies.
📈 BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 data for their bispecific drug pumitamig in non-small cell lung cancer.
💉 The investigational PD-L1xVEGF-A bispecific immunomodulator shows robust activity when combined with chemotherapy in first-line treatment.
📊 Confirmed objective response rates reached up to 72.7% in squamous NSCLC and 63.6% in non-squamous NSCLC at the lower dose level.
🎯 High efficacy was observed across all PD-L1 expression subgroups, including patients with low expression (TPS < 1%).
💊 The drug demonstrated a manageable safety profile with a low treatment discontinuation rate and limited high-grade immune-related adverse events.
🌍 The data were presented as an oral session at the 2026 ASCO Annual Meeting in Chicago based on an April 2026 data cut-off.
🏗️ Pumitamig is advancing through a global Phase 3 development program including the pivotal ROSETTA Lung-02 trial currently recruiting for its final part.
🔄 Two additional global Phase 3 trials, ROSETTA Lung-201 and ROSETTA Lung-202, are enrolling patients to compare pumitamig against standard-of-care therapies like durvalumab and pembrolizumab.
💬 Lead investigator Solange Peters stated that targeting the PD-L1 pathway alone is insufficient for durable responses in advanced disease.
🤝 Co-founder Özlem Türeci highlighted the potential of the bispecific molecule to enhance anti-tumor responses by simultaneously targeting PD-L1 and VEGF-A.
🎯 Senior Vice President Anne Kerber emphasized the goal of improving outcomes for patients left behind by current therapies in this challenging disease.
⚠️ Grade 3 or higher treatment-related adverse events occurred in 48.8% of patients, though only one severe bleeding event was recorded.
📉 Discontinuation due to pumitamig-related adverse events was reported in 9.3% of the patients studied during this interim analysis.
🧬 The Phase 2 portion of the trial evaluated two different dose levels, with higher efficacy noted at the lower dose compared to the higher one.
🩺 Disease control rate (DCR) reached 100% in the patient population evaluated, indicating strong stabilization of the disease for all responders.
Bullish Signals
Robust antitumor activity in NSCLC across all PD-L1 levels.
Lower doses achieved high response rates: 63.6% non-squamous and 72.7% squamous.
Perfect interim disease control rate of 100% in all patients.
Manageable safety with only 9.3% discontinuation rate due to low adverse events.
Advancing global Phase 3 program with two additional pivotal trials enrolling.
Risk Factors
Only rapid oral abstract presented; full publication pending.
100% response limited to narrow TPS ≥ 50% subgroup.
9.3% discontinued due to pumitamig toxicity concerns.
Bullish Signals
Pumitamig demonstrated robust and consistent antitumor activity in first-line non-small cell lung cancer across all PD-L1 expression levels, including TPS < 1%, TPS 1-49%, and TPS ≥ 50%.
The lower dose of pumitamig plus chemotherapy achieved the highest confirmed objective response rates, with 63.6% in non-squamous subtypes and an exceptional 72.7% in squamous subtypes.
At the interim analysis, the drug combination showed a perfect disease control rate (DCR) of 100% across all evaluated patients.
Pumitamig exhibited a manageable safety profile with only a low discontinuation rate of 9.3%, driven by four treatment-related adverse events in 48.8% of patients.
The company is advancing the asset through a comprehensive global Phase 3 development program, with two additional pivotal Phase 3 trials currently enrolling alongside the ROSETTA Lung-02 trial.
BioNTech and Bristol Myers Squibb are accelerating development with a broad registrational plan covering multiple disease stages, including new combination trials with antibody-drug conjugates.
Risk Factors
The interim data from the ROSETTA Lung-02 trial was presented only as a rapid oral abstract at the ASCO Annual Meeting, indicating that full publication has not yet occurred.
Although the confirmed objective response rate reached 100% for patients with TPS ≥ 50%, this represents a very narrow subgroup compared to broader populations where efficacy is lower (47.6%).
Bleeding events occurred in 20.9% of patients, which poses safety concerns given that the mechanism involves inhibiting VEGF-A, typically associated with vascular risks.
Grade ≥ 3 treatment-related adverse events were reported in 48.8% of patients, representing a significant burden for advanced cancer patients already facing toxicity from chemotherapy.
Four patients (9.3%) discontinued treatment due to pumitamig-related adverse events, raising questions about long-term tolerability at the interim analysis stage.
C4 Therapeutics stock rallied on Friday, reaching a 52-week high after Bristol-Myers Squibb released positive late-stage clinical trial data for its new treatment targeting multiple myeloma, a type of blood cancer. C4 shares surged due to the similarity between Bristol-Myers' drug and C4's own lead asset, which is also in development for treating the same condition. The news provided validation for C4 Therapeutics' pipeline as investors reacted positively to the comparative success of a larger pharmaceutical partner's similar compound.
📈 C4 Therapeutics stock hit a 52-week high on positive BMS trial data.
💊 Strong survival results in late-stage multiple myeloma trials drove the surge.
🔬 Bristol-Myers Squibb's treatment resembles C4's lead candidate asset closely.
📈 C4 Therapeutics (CCCC) stock reached a 52-week high on Friday following positive news from Bristol-Myers Squibb.
💊 The price surge was driven by strong survival data generated in a late-stage trial for multiple myeloma, a blood cancer.
🔬 Bristol-Myers Squibb's treatment is similar to C4 Therapeutics' lead candidate asset.
📅 The news was published on May 29, 2026, by Seeking Alpha News Editor Dulan Lokuwithana.
🏢 Bristol-Myers Squibb trades under the ticker symbol BMY on the NYSE.
🧬 C4 Therapeutics trades under the ticker symbol CCCC on the NASDAQ.
📊 The article is categorized under "On the Move" financial news.
Bullish Signals
C4 Therapeutics (CCCC) hit 52-week high after Bristol-Myers Squibb news.
Bristol-Myers Squibb drug validated CCCC's lead candidate with survival data.
Risk Factors
Article lacks negative aspects, risks, or downside catalysts.
Focuses only on positive developments for BMY and CCCC.
Bullish Signals
C4 Therapeutics (CCCC) stock reached a 52-week high following positive news from Bristol-Myers Squibb.
Bristol-Myers Squibb's multiple myeloma drug generated impressive survival data in a late-stage trial, validating the therapeutic approach for CCCC's lead candidate.
Risk Factors
The article focuses entirely on positive developments for Bristol-Myers Squibb (BMY) and C4 Therapeutics (CCCC), noting that CCCC reached a 52-week high.
No negative aspects, risks, or downside catalysts are mentioned in the provided text.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)